Prime Medicine: ARCH Venture Partners, Nelsen Robert Buy 6M Shares at $3.3/Share

Prime Medicine, Inc. (PRME) has reported that ARCH Venture Partners XII, LLC, a 10% owner of the company, acquired 3,003,000 shares at $3.30 per share on August 1, 2025. Additionally, Robert Nelsen, a director and 10% owner of Prime Medicine, also purchased 3,003,000 shares at $3.30 per share on the same date.

ARK Investment Management, led by Cathie Wood, has been actively managing its ETFs with a focus on disruptive innovation. On July 31, 2025, ARK made several strategic trades, including significant investments in Prime Medicine Inc (NASDAQ:PRME) and PagerDuty Inc (NYSE:PD), while also divesting some holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) [1].

ARK purchased 2,356,661 shares of Prime Medicine Inc for $9,238,111, reflecting a substantial investment in the gene editing technology company. This move underscores ARK's belief in Prime Medicine's potential, which has recently announced the closing of its public offering [2]. On the same day, ARK bought 324,784 shares of PagerDuty Inc, valued at $5,297,227, indicating growing confidence in the company's cloud computing services.

In contrast, ARK sold 78,368 shares of CRISPR Therapeutics AG for $4,520,266, marking a shift in its investment stance on the gene-editing pioneer. Additionally, ARK increased its stake in NVIDIA Corp (NASDAQ:NVDA) by acquiring 4,483 shares worth $803,667, and in Figma Inc (NASDAQ:FIG) by buying 60,000 shares for $1,980,000. These transactions highlight ARK's continued interest in key players in the design and graphics processing sectors.

ARK also reduced its exposure to Adaptive Biotechnologies Corp (NASDAQ:ADPT) by offloading 201,786 shares for $2,106,645. The fund sold shares in other companies, including AeroVironment Inc (NASDAQ:AVAV), Kratos Defense and Security Solutions Inc (NASDAQ:KTOS), and Rocket Lab USA Inc (NASDAQ:RKLB), with total dollar values of $403,842, $580,100, and $398,501, respectively.

These trades reflect ARK's active management approach and its focus on investing in companies that align with its vision of disruptive innovation. Investors and market watchers will be keen to monitor how these trades impact the performance of ARK’s ETFs in the dynamic market landscape.

References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-prime-medicine-sells-crispr-stock-93CH-4164714
[2] https://finance.yahoo.com/news/prime-medicine-announces-closing-public-200100659.html